| 2025-11-06 |
详情>>
内部人交易：
McCarthy Sean A.股份减少101793.00股
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本16943.54万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.07美元,归母净利润914.20万美元,同比去年增长-29.64%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘后发布财报
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益0.22美元,归母净利润2337.10万美元,同比去年增长222.05%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益0.27美元,归母净利润2352.50万美元,同比去年增长70.58%
|
| 2025-04-28 |
股东大会：
将于2025-06-11召开股东大会
会议内容 ▼▲
- 1.To elect three directors with terms to expire at the 2028 Annual Meeting of Stockholders;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve the amendment and restatement of CytomX’s 2015 Equity Incentive Plan;
4.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;
5.To conduct any other business properly brought before the 2025 Annual Meeting of Stockholders.
|
| 2025-03-06 |
详情>>
业绩披露：
2024年年报每股收益0.38美元,归母净利润3186.90万美元,同比去年增长5700.88%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.15美元,归母净利润1299.30万美元,同比去年增长1024.11%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益0.09美元,归母净利润725.70万美元,同比去年增长265.01%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益0.17美元,归母净利润1379.10万美元,同比去年增长516.52%
|
| 2024-05-01 |
复牌提示：
2024-05-01 10:14:19 停牌，复牌日期 2024-05-01 10:19:19
|
| 2024-04-04 |
股东大会：
将于2024-05-15召开股东大会
会议内容 ▼▲
- 1.To elect three directors with terms to expire at the 2027 Annual Meeting of Stockholders;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 shares to 300,000,000 shares;
4.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;
5.To conduct any other business properly brought before the 2024 Annual Meeting of Stockholders.
|
| 2024-03-11 |
详情>>
业绩披露：
2023年年报每股收益-0.01美元,归母净利润-56.9万美元,同比去年增长99.43%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.02美元,归母净利润-140.6万美元,同比去年增长98.45%
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.07美元,归母净利润-439.8万美元,同比去年增长92.85%
|
| 2023-04-27 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.To elect two directors with terms to expire at the 2026 Annual Meeting of Stockholders;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;
4.To conduct any other business properly brought before the 2023 Annual Meeting of Stockholders.
|
| 2022-04-27 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.To elect two directors with terms to expire at the 2025 Annual Meeting of Stockholders;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;
4.To conduct any other business properly brought before the 2022 Annual Meeting of Stockholders.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-28 |
股东大会：
将于2021-06-16召开股东大会
会议内容 ▼▲
- 1.To elect two directors with terms to expire at the 2024 Annual Meeting of Stockholders;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;
4.To conduct any other business properly brought before the 2021 Annual Meeting of Stockholders.
|
| 2020-04-29 |
股东大会：
将于2020-06-17召开股东大会
会议内容 ▼▲
- 1.To elect three directors with terms to expire at the 2023 Annual Meeting of Stockholders;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 75,000,000 shares to 150,000,000 shares;
4.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;
5.To conduct any other business properly brought before the 2020 Annual Meeting of Stockholders.
|
| 2019-04-26 |
股东大会：
将于2019-06-19召开股东大会
会议内容 ▼▲
- 1.To elect two directors with terms to expire at the 2022 Annual Meeting of Stockholders;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To approve, on a nonbinding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;
4.To hold a non-binding advisory vote on the frequency of future advisory votes by stockholders on the compensation of the Company’s named executive officers;
5.To conduct any other business properly brought before the 2019 Annual Meeting of Stockholders.
|
| 2018-04-26 |
股东大会：
将于2018-06-13召开股东大会
会议内容 ▼▲
- 1.To elect two directors with terms to expire at the 2021 Annual Meeting of Stockholders;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To conduct any other business properly brought before the 2018 Annual Meeting of Stockholders.
|
| 2017-05-09 |
股东大会：
将于2017-06-20召开股东大会
会议内容 ▼▲
- 1. To elect three directors with terms to expire at the 2020 Annual Meeting of Stockholders;
2. To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To conduct any other business properly brought before the 2017 Annual Meeting of Stockholders.
|
| 2016-04-28 |
股东大会：
将于2016-06-10召开股东大会
会议内容 ▼▲
- 1.To elect one director with term to expire at the 2019 Annual Meeting of Stockholders;
2.To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.To adopt and approve the CytomX Therapeutics, Inc. Annual Incentive Plan;
4.To approve the performance measures included in the CytomX Therapeutics, Inc. 2015 Equity Incentive Plan;
5.To conduct any other business properly brought before the 2016 Annual Meeting of Stockholders.
|